LC-ESI-MS/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 879, Issue 11-12, 2011, Pages 769-776

  Challa, Balasekhara Reddy ^a   Awen, Bahlul Z ^b   Chandu, Babu Rao ^b   Rihanaparveen, Shaik ^c  

^a Nalanda Educational Society   (India)

^b Aljabal Algharbi University   (Libyan Arab Jamahiriya)

^c JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Bioequivalence; Entecavir; Liquid chromatography; Mass spectrometry; Pharmacokinetics

Indexed keywords

AMMONIUM HYDROGEN CARBONATE; BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; BIOLOGICAL MATRIXES; CHROMATOGRAPHIC SEPARATIONS; CORRELATION COEFFICIENT; ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; ENTECAVIR; FREEZE/THAW CYCLES; HEALTHY HUMANS; HUMAN PLASMAS; INTERNAL STANDARDS; ISOCRATIC MOBILE PHASE; LAMIVUDINE; LC-ESI-MS/MS; LINEAR CONCENTRATION; MULTIPLE REACTION MONITORING; ORAL ADMINISTRATION; PLASMA SAMPLES; POSITIVE MODE; POSTOPERATIVE STUDY; PROTON ADDUCTS; QUANTITATIVE ESTIMATION; SOLID PHASE EXTRACTION METHOD;

AMMONIUM COMPOUNDS; CHROMATOGRAPHY; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; EXTRACTION; LAGRANGE MULTIPLIERS; LIQUIDS; MASS SPECTROMETRY; METHANOL; PHARMACOKINETICS; PLASMA (HUMAN);

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

ENTECAVIR; LAMIVUDINE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GUANINE; HUMANS; LAMIVUDINE; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 79952897522     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2011.02.023     Document Type: Article

References (13)

1. http://www.drugban.ca/drugs/DB00442.
2. Yao G. J. Antimicrob. Chemother. 2007, 60:201.
3. Rivkin A. Drugs Today (Barc.) 2007, 43:201.
4. Amano M., Goto A. Nippon Yakurigaku Zasshi 2007, 129:287.
5. Sims K.A., Woodland A.M. Pharmacotherapy 2006, 26:1745.
6. Yan J.H., Bifano M., Olsen S., Smith R.A., Zhang D., Grasela D.M., LaCreta F. J. Clin. Pharmacol. 2006, 46:1250.
7. Rivkin A. Curr. Med. Res. Opin. 2005, 21:1845.
8. Dalmora S.L., Sangoi M.S., Nogueira D.R., Da Silva L.M. J. AOAC Int. 2010, 93:523.
9. Desai D., Rao V., Guo H., Li D., Bolgar M. Int. J. Pharm. 2007, 342:87.
10. Zhang D., Fu Y., Gale J.P., Aubry A.F., Arnold M.E. J. Pharm. Biomed. Anal. 2009, 49:1027.
11. Guidance for Industry: Bioanalytical Method Validation May 2001, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for biologics evaluation and research (CBER).
12. Guidance for Industry Food-Effect Bio Availability and Fed Bio Equivalence Studies December 2002, U.S. Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research (CDER).
13. Guidance for industry bio availability and fed bio equivalence studies for orally administered drug products-general considerations March 2003, U.S. Department of health and human services food and drug administration centre for drug evaluation and research (CDER).